Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Iovance Biotherapeutics (IOVA) over the last 15 years, with Dec 2024 value amounting to $390.7 million.

  • Iovance Biotherapeutics' Cash from Financing Activities rose 109.89% to $88.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.9 million, marking a year-over-year decrease of 36.58%. This contributed to the annual value of $390.7 million for FY2024, which is 15.62% down from last year.
  • As of FY2024, Iovance Biotherapeutics' Cash from Financing Activities stood at $390.7 million, which was down 15.62% from $463.0 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Cash from Financing Activities registered a high of $576.4 million during FY2020, and its lowest value of $190.2 million during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $390.7 million (2024), whereas its average is $347.9 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Cash from Financing Activities skyrocketed by 9,301.76% in 2020, and later crashed by 58.49% in 2021.
  • Over the past 5 years, Iovance Biotherapeutics' Cash from Financing Activities (Yearly) stood at $576.4 million in 2020, then plummeted by 58.49% to $239.3 million in 2021, then fell by 20.53% to $190.2 million in 2022, then soared by 143.47% to $463.0 million in 2023, then declined by 15.62% to $390.7 million in 2024.